Navigation Links
MedImmune Advances Asthma Program With Start of Phase 2 Clinical Trial for Antibody Targeting IL-5 Receptor
Date:12/4/2008

GAITHERSBURG, Md., Dec. 4 /PRNewswire/ -- MedImmune today announced that it has initiated a Phase 2 clinical trial in patients with chronic asthma to determine the safety of subcutaneous dosing of a humanized monoclonal antibody (MAb) that targets the interleukin-5 receptor (IL-5R). Preclinical data suggest that inhibiting the IL-5R pathway may lead to a targeted approach for treating patients with asthma, supporting continued study of this antibody.

"Asthma can be a very debilitating disease, and despite current therapies, patients are in need of novel treatment options," said Nestor Molfino, M.D., vice president, clinical development, pulmonary disease. "Some asthmatics may show an increased circulation of eosinophils in blood -- a certain type of white blood cell believed to play a critical role in the severity and disease pathway of asthma; therefore administration of this antibody may increase asthma control."

MEDI-563, which was generated using BioWa's POTELLIGENT(TM) Technology platform, has previously been investigated in a Phase 1 open-label dose-escalating study to evaluate the safety and tolerability of a single intravenous infusion in adults with mild-to-moderate asthma. Data from the completed Phase 1 study demonstrated that the antibody was well-tolerated with biologic activity producing substantial and prolonged depletion of blood eosinophils, thus supporting its continued development. Published literature suggests that reduction of eosinophils in sputum was associated with better asthma control and increases in sputum eosinophilia were associated with exacerbations of asthma. The antibody is also currently being evaluated in a double-blind, placebo-controlled Phase 1 study to evaluate the safety and tolerability and effects of the antibody on airway eosinophils in adults with asthma.

About Interleukin-5 Receptor (IL-5R)

Interleukin-5 is a cytokine secreted predominantly
'/>"/>

SOURCE MedImmune
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. MedImmune Announces Zook as President
2. MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology
3. MedImmune Licenses Reverse Genetics Technology to Hungarys Omninvest for Use in Influenza Vaccine Development and Production
4. MedImmune Expands R&D Capacity with New Research Facility in Cambridge, U.K.
5. MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease
6. Pinnacle Biologics Announces Stock Purchase Agreement With MedImmune
7. MedImmunes Brian Rosen Honored by Montgomery County Chamber at 49th Annual Awards Dinner
8. Depth of MedImmunes Respiratory Disease Research Program Highlighted at Annual Meeting of the American Thoracic Society
9. MedImmune Fortifies Strategic Scientific Portfolio Management and International Leadership With New Executive Appointments
10. MedImmune Presents Data Highlighting its Progressive Oncology Portfolio at Annual Meeting of the American Association For Cancer Research
11. Seneca Valley High School Student Receives Science Award From MedImmune
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... In contrast to traditional LED lights where ... Valoya uses proprietary LED technology to incorporate their spectra ... which is critical in low proximity installations. The Valoya ... its lifetime which is up to four times longer ... investment cost was clearly higher when compared to traditional ...
(Date:12/19/2014)... , Dec. 18, 2014 Egenix, Inc. is pleased ... elected Chairman of the Board, to succeed Donald Fresne ... but will continue as a member of the Board.  In ... added to the company over almost twenty years, the Board ... Board of Directors has established a Search Committee to find ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 Based ... the overall surgical imaging market is dominated by ... the surgical imaging market. These players include GE ... Ziehm Imaging (Germany). , Full Report Copy ... of GE Healthcare can be attributed to its ...
(Date:12/17/2014)... Once more, EMAAR has selected ... waste water treatment plant to phase one of BayLaSun, ... Two years ago Bioshaft successfully supplied and operated a ... residential towers with an occupancy of 900 residences. ... gallons per day and was signed on September 16th, ...
Breaking Biology Technology:Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 4
... called excitons so effectively that they condensed and cohered ... will allow scientists to better study the physical properties ... applications as diverse as efficient harvesting of solar energy ... condensate in a trap opens the opportunity to study ...
... Researchers are edging toward the creation of new ... transmission of light, with potential applications including advanced ... - layers of silver and titanium oxide and ... the properties of light. The light becomes "hyperbolic," ...
... LONDON, May 25, 2012 Increasingly, big pharma is viewing ... that would enable them to focus on their core ... patent expiry of key blockbuster drugs worth $45 billion ... the capacity utilisation rates of their manufacturing facilities, thereby ...
Cached Biology Technology:Exotic particles, chilled and trapped, form giant matter wave 2'Metamaterials,' quantum dots show promise for new technologies 2Rising Interest of Big Pharma Creates Immense Growth Potential for Contract Manufacturing Organisations, Says Frost & Sullivan 2Rising Interest of Big Pharma Creates Immense Growth Potential for Contract Manufacturing Organisations, Says Frost & Sullivan 3Rising Interest of Big Pharma Creates Immense Growth Potential for Contract Manufacturing Organisations, Says Frost & Sullivan 4
(Date:12/17/2014)... DUBLIN , Dec. 16, 2014 Research ... announced the addition of the "Global Chemical ... http://photos.prnewswire.com/prnh/20130307/600769 ... is the increasing demand for medical sensors in ... patient data for quick and correct diagnosis during ...
(Date:12/11/2014)... 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of ... 2015-2019"  report to their offering. ... advances in technology. With continuous advances in technology, ... the latest standard that meets the needs and ...
(Date:12/11/2014)... 10, 2014  Data Sciences International (DSI), the ... a new series of digital telemetry implants to ... M series, part of the PhysioTel™ Digital platform, ... possible physiologic data when incorporating functional endpoints into ... to toxicology studies has evolved from short ECG ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
... Jan. 10, 2011 Aware, Inc. (Nasdaq: AWRE ... telecommunications and biometrics industries, today announced that on January 5, ... Jr. and John S. Stafford, III to the Aware Board ... a Class III Director and will serve on the Board,s ...
... by Josh LaBaer,s research team in the Biodesign Institute at ... gene targets ---including several novel genes---that are involved in drug ... the study may one day aid in the treatment of ... cancer, by empowering physicians with a more personalized approach to ...
... Large hypoxic zones low in oxygen long have been ... a Purdue University study shows that while these so-called ... are impacted equally. Tomas Höök, an assistant professor ... researcher Kristen Arend used output from a model to ...
Cached Biology News:Aware Announces Appointment of New Directors 2Aware Announces Appointment of New Directors 3Study identifies new genetic signatures of breast cancer drug resistance 2Study identifies new genetic signatures of breast cancer drug resistance 3Lake Erie hypoxic zone doesn't affect all fish the same, study finds 2
... Mouse anti-Yersinia pestis F1 antigen, ... Applications: ELISA: Use at ... at an assay dependent dilution. WB: ... Predicted molecular weight: 18 kDa. Not ...
Anti-Phospho-JKK/SEK1/MKK4 pAb Description: 100 g rabbit polyclonal antibody. Reacts with human/mouse/rat. Tested in WB. Research Focus: signal transduction Storage: -20C Shipping Tem...
... Reagent A - Fixation medium Reagent ... are intended for fixing cells in suspension ... cells with Reagent B. This procedure gives ... the morphological scatter characteristics of the cells ...
... is formulated for covering tissue sections and cell preparations immunohistochemically ... products. , ... Application: Vision ... AEC that require an aqueous mounting medium, or those that ...
Biology Products: